Search

Displaying results 3221 - 3230 of 10000 in total
  1. Drug

    Virus Specific T-Cell

    go.drugbank.com/drugs/DB15735
    Investigational

    Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and activation. … These T-cells are then isolated from the donor and expanded in a culture to generate more VSTs.

  2. Drug

    Avanafil

    go.drugbank.com/drugs/DB06237
    Approved

    Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. … In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively

    Products: STENDRA 100 MG TABLET, 2 ADET, STENDRA 100 MG TABLET, 4 ADET
  3. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary

    Products: UPTRAVI 200 MCG FILM KAPLI TABLET, 60 ADET, UPTRAVI 400 MCG FILM KAPLI TABLET, 60 ADET
  4. Drug

    CK0802

    go.drugbank.com/drugs/DB15866
    Investigational

    CK0802 is an off-the-shelf product composed of allogeneic umbilical cord blood derived regulatory T-cells (T-Reg cells), which can be used intravenously and without HLA matching. … [L16358] On the surface of these T-Reg cells, T-cell lung homing markers are expressed.

  5. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    ], a CFTR potentiator, for the treatment of patients with responsive CFTR mutations. … It is used alongside other CFTR correctors and CFTR potentiators to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.

  6. Drug

    Palladium Pd-103

    go.drugbank.com/drugs/DB15016
    Experimental

    Palladium Pd-103 is under investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial).

  7. Target

    8-amino-7-oxononanoate synthase

    go.drugbank.com/bio_entities/BE0001794
    TargetEscherichia coli (strain K12)

    Catalyzes the decarboxylative condensation of pimeloyl-[acyl-carrier protein] and L-alanine to produce 8-amino-7-oxononanoate (AON), [acyl-carrier protein], and carbon dioxide. Can also use pimeloyl-CoA instead of pimeloyl-ACP as substra...

    Synonyms: 7-KAP synthase
  8. Drug

    Odevixibat

    go.drugbank.com/drugs/DB16261
    ApprovedInvestigational

    Odevixibat, or A4250, is an ileal sodium/bile acid cotransporter inhibitor indicated for the treatment of pruritus in patients older than 3 months, with progressive familial intrahepatic cholestasis (PFIC … [L34803] Previous therapies for PFIC included a bile acid sequestrant such as [ursodeoxycholic acid].

  9. Drug

    Larazotide

    go.drugbank.com/drugs/DB05645
    Investigational

    An octapeptide inhibitor of paracellular permeability whose structure is derived from a protein (zonula occludens toxin) secreted by Vibrio cholerae for treatment of Coeliac disease.

  10. Drug

    Irofulven

    go.drugbank.com/drugs/DB05786
    Investigational

    A novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track … MGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis.